The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease.
Аннотация
INTRODUCTION
Anti-tumour necrosis factor (TNF) therapy is increasingly used in the management of inflammatory bowel disease; however, concerns have been raised regarding risk of infection with such drugs. Little is known about their effect upon viral infection.
SOURCES OF DATA: A search of PubMed using the terms 'infliximab', 'etanercept', 'adalimumab' or 'anti-TNF therapy' combined with the names of specific viruses was performed. A search of cited papers was used to identify further relevant reports.
AREAS OF AGREEMENT: Numerous reports of the use of anti-TNF in patients with chronic or latent viral infection appear in the literature. Specific problems related to hepatitis B virus and varicella zoster virus may exist. The safety profile of anti-TNF in chronic viral infection is generally reassuring.
AREAS OF CONTROVERSY: Numerous consensus statements relating to pre-treatment serology or vaccination have recently appeared; however, significant variation exists in their recommendations.
GROWING POINTS: Increasing awareness of the implications of anti-TNF therapy on viral infection may allow safer use of such drugs.
AREAS TIMELY FOR DEVELOPING RESEARCH: The clinical and cost-effectiveness of screening for viral infections prior to anti-TNF requires further study.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.